Anti-aging Therapeutics Market worth $ 2013.5 Million by 2030 - Exclusive Report by InsightAce Analytic
2022-06-08
寡核苷酸小分子药物并购
JERSEY CITY, N.J., June 8, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on
"Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others), Mechanism of Action (Senolytic, Cell Regeneration, mTOR inhibitor/Modulator, AMP-kinase/AMP Activator, Mitochondria Inhibitor/Modulator and Others))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030"
According to the latest research by InsightAce Analytic, the global Anti-aging Therapeutics market size valued at US$ 518.86 million in 2021, and it is expected to reach US$ 2013.51 million in 2030, recording a promising CAGR of 16.53% during the period of 2022-2030.
Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1249
Aging populations are increasing the prevalence of age-related illnesses, causing individual and social concerns. The demand for effective regenerative medicine solutions for the elderly is higher than ever. Anti-Aging Therapeutics has emerged as a new medical science field. Anti-aging diagnosis and medicine, which is a subset of medical and healthcare, uses modern science and medical technology to identify, prevent, cure, and reverse age-related dysfunctions, illnesses, and diseases. Several cell, insect, and animal models may be useful beginning areas in the development of anti-aging medicines prior to human trials.
Interest and expenditure in anti-aging medicines are rising exponentially as living conditions improve. Several companies have also focused their efforts on stem cells and regenerative medicine. Given the numerous applications of stem cells, applications in regenerative medicine are far beyond ageing disorders and illnesses. Nonetheless, a few organizations have concentrated specifically on age-related problems. For instance, In Feb 2021, Cambrian Biopharma received $60 million in private funding for the development of anti-aging medications. The "Nine Hallmarks of Aging," which include cellular senescence, persistent tissue inflammation, and mitochondrial malfunction, are the focus of research of Cambrian scientists. Researchers are utilizing advancements in immunology, genomics, and epigenetics, as well as technologies ranging from gene editing to novel stem cell treatments.
There is substantial potential for anti-aging therapeutics companies that effectively launch longevity treatments. Despite these encouraging breakthroughs in the field of ageing, a number of barriers will become obvious once an anti-aging medicine undergoes the demanding clinical trial procedure.
Market growth is primarily related to a rise in demand for individualized, precise, preventative, and participative ageing therapies, as well as an increase in the Geriatric Population. As a result, as the number of the elderly rises, so does the need for anti-aging treatments. Increased technological advancements and R&D spending on anti-ageing products are propelling the market forward. To meet the growing demand for technologically advanced solutions among customers, companies in the field have mainly developed revolutionary anti-ageing therapeutics products.
With a rising healthcare industry, North America is expected to have the largest revenue shares in 2022.
Research and development into pharmaceuticals are rising in major economies such as the United States and Canada, and this is due to the increased investment in pharmaceutical design, production as well as research into senescent cells. Moreover, Asia Pacific is the world's most populous region, and it has a sizable market for anti-aging therapeutics. The ever-increasing proportion of elderly people in the population is a potential customer base for anti-aging treatments, driving regional growth.
Enquiry Before Buy:
https://www.insightaceanalytic.com/enquiry-before-buying/1249
Major key Players in the Anti-aging Therapeutics market are AgelessRx, ANOVA Institute for Regenerative Medicine, Betterhumans, BioAge Labs, BIOPHYTIS BSA, bioXcellerator, Cambrian Biopharma, CytoMed Therapeutics, Gero.ai, Rejuvenate Bio, Rejenevie Therapeutics, UT Health San Antonio, MyMD Pharmaceuticals, Intervene Immune, Inc. , CohBar, Inc., Alkahest, Athersys Inc, BHB Therapeutics, Biosplice, Cyclo Therapeutics, Denali Therapeutics, Elysium Health, Genome Protection, GenSight Biologics, Intervene Immune, Khondrian, Longeveron, LyGenesis, Mesoblast, Minovia Therapeutics, Mitobridge, Navitor Pharmaceuticals, NeuroTrack, Nuchido, NuSirt, OneSkin Technologies, PharmatrophiX, Proteostasis Therapeutics, Retrotope, Stealth Biotherapeutics, TA Sciences, Unity Biotechnology Younger Phenotype, and Other Prominent Players
Recent Key Developments:
In Feb 2022, Cambrian Biopharma announced that it had entered into a licence arrangement with Novartis to promote innovative, selective drugs that target the mechanistic target of rapamycin (mTOR) pathway. These compounds were conceived and characterized by Novartis. Cambrian Biopharma informed via a statement that the licensed assets are structural analogues of the FDA-approved drug rapamycin. This drug has been shown to prevent or reverse multiple age-related health deficits in mice and to extend their average lifespan by up to 31 %, according to the information provided by Cambrian Biopharma.
In May 2019, Rejenevie™ Therapeutics announced the initiation of the Company's Phase II clinical trial to explore the safety and effectiveness of its unique AR-100 immune restoration treatment to increase the function of the ageing immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration medicines targeting age-related disorders.
In April 2022, MyMD Pharmaceuticals Inc. accelerated the dosing of additional patients in the Company's fully funded Phase 2 clinical study of lead drug candidate MYMD-1 as a treatment for delaying ageing and extending a healthy lifespan. The double-blind, placebo-controlled, randomized Phase 2 research (NCT05283486) explores the effectiveness, safety, and pharmacokinetics of MYMD-1® in the treatment of people aged 65 years or older with chronic inflammation associated with sarcopenia/frailty.
Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Type of Molecule
Biologics
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Type of Aging
Cellular Aging
Immune Aging
Metabolic Aging
Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Mechanism of Action
Cell Regeneration
mTOR inhibitormTOR inhibitor/Modulator
AMP-kinase/AMP Activator
Mitochondria Inhibitor/Modulator
Others
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on
Region
North America
Europe
Latin America
Middle East & Africa
North America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030
U.S.
Canada
Europe Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030
India
China
Japan
South Korea
Australia & New Zealand
Latin America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030
Brazil
Mexico
Rest of Latin America
Middle East & Africa Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030
GCC Countries
South Africa
Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for global Anti-aging Therapeutics market
To receive industry overview and future trends of global Anti-aging Therapeutics market
To analyse the Anti-aging Therapeutics market drivers and challenges
To get information on Anti-aging Therapeutics market size value (US$ Mn) forecast till 2030
Major Investments, Mergers & Acquisition in global Anti-aging Therapeutics market industry
For Customization @
https://www.insightaceanalytic.com/customisation/1249
Other Related Reports Published by InsightAce Analytic:
Global Longevity and Anti-Senescence Therapy Market
Global Antisense Oligonucleotide Therapeutics Market
Global Anti-Ageing Products Services and Devices Market
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
SOURCE InsightAce Analytic Pvt. Ltd.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。